Worrying heart signal may impact hopes for early approval of osteoporosis drug

22 May 2017
2019_biotech_test_vial_discovery_big

Belgian drugmaker UCB (Euronext: UCB) and US biotech Amgen (Nasdaq: AMGN) have announced strong efficacy data from their Evenity (romosozumab) study, but a worrying safety signal caused shares in UCB to fall more than 10%.

The trial into Evenity, which is under co-development as a therapy for postmenopausal women with osteoporosis, met both primary endpoints and the key secondary endpoint.

However, a new safety signal was observed - a greater number of serious adverse events for the test group, 2.5% for romosozumab versus 1.9% for alendronate, at 12 months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology